This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishida, T. Articles by Ueda, R. Search for Related Content PubMed PubMed Citation Articles by Ishida, T. Articles by Ueda, R.

Clinical Significance of CCR4 Expression in Adult T-Cell Leukemia/Lymphoma

Its Close Association with Skin Involvement and Unfavorable Outcome¹

Department of Internal Medicine and Molecular Science [T. I., S. I., M. I., H. K., R. U.] and Department of Clinical Pathology [H. I., S. S., T. E.], Nagoya City University Graduate School of Medical Science, Nagoya 467-8601; Department of Hematology, Imamura Bun-in Hospital [A. U., Y. T.]; Department of Hematology, Shizuoka Saiseikai General Hospital [S. K., G. T.]; Division of Transfusion Medicine, Nagoya City University Hospital [A. W.]; and Department of Molecular Preventive Medicine and Core Research and Evolutional Science and Technology, University of Tokyo [K. M.], Tokyo, Japan

Adult T-cell leukemia/lymphoma (ATLL) is a distinct clinical entity among mature T-cell neoplasms, and its causative agent has been confirmed to be long-term infection by human T-lymphotropic virus type 1. A recent study demonstrated frequent expression of a chemokine receptor, CC chemokine receptor (CCR)4, which is known as a Th2 marker but not CXC chemokine receptor (CXCR)3, which is known as a Th1 marker, among both ATLL- and human T-lymphotropic virus type 1-immortalized T cells. In this study, immunostaining analysis for CCR4 and CXCR3 expression in ATLL cells obtained from 103 patients with ATLL was performed, and the clinical parameters and overall survival of the CCR4-positive and -negative cases were compared. Ninety-one (88.3%) of the 103 cases were positive for CCR4 staining, whereas only 5 (4.9%) were positive for CXCR3 staining. Positivity for CCR4 was significantly associated with skin involvement (P < 0.05), although there were no significant differences in clinical characteristics between the CCR4-positive and -negative cases at the time of initial diagnosis. CCR4⁺ ATLL cells may accumulate in the skin because of the expression of a CCR4 ligand, thymus and activation-regulated chemokine (TARC), on normal and inflamed cutaneous endothelia. As for survival analysis, positivity for CCR4 expression was extracted as an unfavorable prognostic factor as well as other factors, including the presence of B symptoms and extranodal involvement of more than one site. Multivariate analysis confirmed that CCR4 expression was an independent and significant prognostic factor (P < 0.05). Thus, our finding may provide a novel insight into not only the biological but also the clinical features of ATLL.

This article has been cited by other articles:

				X.-J. Qin, H.-Z. Shi, J.-M. Deng, Q.-L. Liang, J. Jiang, and Z.-J. Ye CCL22 Recruits CD4-positive CD25-positive Regulatory T Cells into Malignant Pleural Effusion Clin. Cancer Res., April 1, 2009; 15(7): 2231 - 2237. [Abstract] [Full Text] [PDF]

				K. Tsukasaki, O. Hermine, A. Bazarbachi, L. Ratner, J. C. Ramos, W. Harrington Jr, D. O'Mahony, J. E. Janik, A. L. Bittencourt, G. P. Taylor, et al. Definition, Prognostic Factors, Treatment, and Response Criteria of Adult T-Cell Leukemia-Lymphoma: A Proposal From an International Consensus Meeting J. Clin. Oncol., January 20, 2009; 27(3): 453 - 459. [Abstract] [Full Text] [PDF]

				K. Hieshima, D. Nagakubo, T. Nakayama, A.-K. Shirakawa, Z. Jin, and O. Yoshie Tax-Inducible Production of CC Chemokine Ligand 22 by Human T Cell Leukemia Virus Type 1 (HTLV-1)-Infected T Cells Promotes Preferential Transmission of HTLV-1 to CCR4-Expressing CD4+ T Cells J. Immunol., January 15, 2008; 180(2): 931 - 939. [Abstract] [Full Text] [PDF]

				H. Yano, T. Ishida, A. Inagaki, T. Ishii, J. Ding, S. Kusumoto, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda Defucosylated Anti CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome Clin. Cancer Res., November 1, 2007; 13(21): 6494 - 6500. [Abstract] [Full Text] [PDF]

				S. T. Pals, D. J. J. de Gorter, and M. Spaargaren Lymphoma dissemination: the other face of lymphocyte homing Blood, November 1, 2007; 110(9): 3102 - 3111. [Abstract] [Full Text] [PDF]

				D. Baatar, P. Olkhanud, D. Newton, K. Sumitomo, and A. Biragyn CCR4-Expressing T Cell Tumors Can Be Specifically Controlled via Delivery of Toxins to Chemokine Receptors J. Immunol., August 1, 2007; 179(3): 1996 - 2004. [Abstract] [Full Text] [PDF]

				T. Ishida, T. Ishii, A. Inagaki, H. Yano, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda Specific Recruitment of CC Chemokine Receptor 4-Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege Cancer Res., June 1, 2006; 66(11): 5716 - 5722. [Abstract] [Full Text] [PDF]

				T. Shimauchi, S. Imai, R. Hino, and Y. Tokura Production of Thymus and Activation-Regulated Chemokine and Macrophage-Derived Chemokine by CCR4+ Adult T-Cell Leukemia Cells Clin. Cancer Res., March 15, 2005; 11(6): 2427 - 2435. [Abstract] [Full Text] [PDF]

				T. Ishida, S. Iida, Y. Akatsuka, T. Ishii, M. Miyazaki, H. Komatsu, H. Inagaki, N. Okada, T. Fujita, K. Shitara, et al. The CC Chemokine Receptor 4 as a Novel Specific Molecular Target for Immunotherapy in Adult T-Cell Leukemia/Lymphoma Clin. Cancer Res., November 15, 2004; 10(22): 7529 - 7539. [Abstract] [Full Text] [PDF]

				T. Ishida, H. Inagaki, A. Utsunomiya, Y. Takatsuka, H. Komatsu, S. Iida, G. Takeuchi, T. Eimoto, S. Nakamura, and R. Ueda CXC Chemokine Receptor 3 and CC Chemokine Receptor 4 Expression in T-Cell and NK-Cell Lymphomas with Special Reference to Clinicopathological Significance for Peripheral T-Cell Lymphoma, Unspecified Clin. Cancer Res., August 15, 2004; 10(16): 5494 - 5500. [Abstract] [Full Text] [PDF]

				R. Niwa, E. Shoji-Hosaka, M. Sakurada, T. Shinkawa, K. Uchida, K. Nakamura, K. Matsushima, R. Ueda, N. Hanai, and K. Shitara Defucosylated Chimeric Anti-CC Chemokine Receptor 4 IgG1 with Enhanced Antibody-Dependent Cellular Cytotoxicity Shows Potent Therapeutic Activity to T-Cell Leukemia and Lymphoma Cancer Res., March 15, 2004; 64(6): 2127 - 2133. [Abstract] [Full Text] [PDF]